Compound repurposing
Small molecule compounds are being studied for repurposing in COVID-19 treament and research. Multiple small molecules that are approved to treat other disorders have shown potential effects on key proteins involved in SARS-CoV-2 host cell entry and replication. Repurposing of existing compounds is advantageous for speed - reducing timescales compared to conventional drug discovery. Researchers can save up to 50% on these small molecules for COVID-19 research, as they are up to half the price of other suppliers.
Quetiapine hemifumarate (HB1803)
Description:5-HT2 and D2 antagonist. Atypical antipsychotic.
Purity:>99%
Spiperone hydrochloride (HB1656)
Description:Selective D2-like receptor antagonist. 5-HT2A antagonist.
Purity:>98%
(S)-(-)-Sulpiride (HB1836)
Description:Selective D2-like receptor antagonist. Active enantiomer.
Purity:>99%
(RS)-(±)-Sulpiride (HB1835)
Description:Standard D2-like dopamine receptor antagonist
Purity:>98%
WAY 100635 maleate (HB1790)
Description:Potent 5-HT1A receptor antagonist. D4 receptor agonist.
Purity:>99%
Ziprasidone hydrochloride (HB1753)
Description:5-HT2A and D2 antagonist. Atypical antipsychotic.
Purity:>99%